European intensive care physicians’ experience of infections due to antibiotic-resistant bacteria

Author:

Lepape Alain,Jean Astrid,De Waele Jan,Friggeri Arnaud,Savey Anne,Vanhems Philippe,Gustin Marie Paule,Monnet Dominique L.,Garnacho-Montero José,Kohlenberg Anke

Abstract

Abstract Background Antimicrobial resistance (AMR) compromises the treatment of patients with serious infections in intensive care units (ICUs), and intensive care physicians are increasingly facing patients with bacterial infections with limited or no adequate therapeutic options. A survey was conducted to assess the intensive care physicians’ perception of the AMR situation in the European Union/European Economic Area (EU/EEA). Methods Between May and July 2017, physicians working in European ICUs were invited to complete an online questionnaire hosted by the European Society of Intensive Care Medicine. The survey included 20 questions on hospital and ICU characteristics, frequency of infections with multidrug-resistant (MDR) bacteria and relevance of AMR in the respondent’s ICU, management of antimicrobial treatment as well as the use of last-line antibiotics in the six months preceding the survey. For the analysis of regional differences, EU/EEA countries were grouped into the four sub-regions of Eastern, Northern, Southern and Western Europe. Results Overall, 1062 responses from four European sub-regions were analysed. Infections with MDR bacteria in their ICU were rated as a major problem by 257 (24.2%), moderate problem by 360 (33.9%) and minor problem by 391 (36.8%) respondents. Third-generation cephalosporin-resistant Enterobacteriaceae were the most frequently encountered MDR bacteria followed by, in order of decreasing frequency, meticillin-resistant Staphylococcus aureus, carbapenem-resistant Enterobacteriaceae, carbapenem-resistant Pseudomonas aeruginosa and vancomycin-resistant enterococci. Perception of the relevance of the AMR problem and the frequency of specific MDR bacteria varied by European sub-region. Bacteria resistant to all or almost all available antibiotics were encountered by 132 (12.4%) respondents. Many physicians reported not having access to specific last-line antibiotics. Conclusions The percentage of European ICU physicians perceiving AMR as a substantial problem in their ICU is high with variation by sub-region in line with epidemiological studies. The reports of bacteria resistant to almost all available antibiotics and the limited availability of last-line antibiotics in ICUs in the EU/EEA are of concern.

Funder

European Centre for Disease Prevention and Control

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Infectious Diseases,Microbiology (medical),Public Health, Environmental and Occupational Health

Reference32 articles.

1. Kollef MH, Bassetti M, Francois B, Burnham J, Dimopoulos G, Garnacho-Montero J, et al. The intensive care medicine research agenda on multidrug-resistant bacteria, antibiotics, and stewardship. Intensive Care Med. 2017 Sep;43(9):1187–97.

2. European Centre for disease prevention and control. Summary of the latest data on antibiotic consumption in the European Union - ESAC-net surveillance data. Stockholm: ECDC. November 2016:2016 Available from: https://ecdc.europa.eu/sites/portal/files/documents/antibiotics-ESAC-Net%20Summary%202016_0.pdf.

3. European Centre for Disease Prevention and Control. Last-line antibiotics are failing: options to address this urgent threat to patients and healthcare systems. Stockholm: ECDC; 2016. Available from: https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/antibiotic-resistance-policy-briefing.pdf.

4. Lepape A, Monnet DL. Experience of European intensive care physicians with infections due to antibiotic-resistant bacteria, 2009. Euro Surveill. 2009;14(45).

5. European Centre for Disease Prevention and Control. Surveillance of antimicrobial resistance in Europe 2016. Annual report of the European antimicrobial resistance surveillance network (EARS-net). Stockholm: ECDC; 2017. Available from: https://ecdc.europa.eu/en/publications-data/antimicrobial-resistance-surveillance-europe-2016.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3